Pipeline :: Hepatitis B

Hepatitis B Therapy

Our hepatitis B therapy, DV-601, is currently in phase 1b clinical development. This novel treatment approach, which for the first time combines both the surface and core hepatitis B virus (HBV) antigens, may offer a more effective therapeutic option for patients chronically infected with HBV. We have retained all commercial rights to this product.

Commercial Opportunity

Over 350 million individuals worldwide are chronically infected with HBV, which can lead to cirrhosis of the liver and liver cancer. The current worldwide market for HBV therapeutics is estimated to be over $1 billion annually and available therapies have modest efficacy.

Our HBV therapy, used in combination with existing antiviral therapies, is expected to induce a potent immune response against HBV-infected cells in the liver to eradicate HBV infection and may offer a more effective therapeutic option for chronically infected patients.